Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS HIMALAYA and IMbrave-150 for Hepatocellular Carcinoma: A
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC? Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021 IMbrave150: The first successful Phase III trial of a cancer
Daniel Catenacci, MD, University of Chicago, Chicago, IL, provides an overview of some of the exciting data presented at this Ask the author session with Prof. Michel Ducreux The IMpower150 study (NCT02366143) showed that atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel
IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and IMbrave150 analysis. Oncologist. 2025 Sep 1;30(9):oyaf269. doi: 10.1093 IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with
Advanced HCC: IMbrave150 Trial IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab
Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150 Updates from IMbrave 150 in HCC IMbrave150: updated overall survival data from a global
First-line treatment options for advanced HCC including sorafenib, lenvatinib, and atezolizumab-bevacizumab as systemic Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial
2021 TASL HCC Single Topic Conference Satellite symposium - Roche Impact of IMbrave150 on theadvanced HCC treatment In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the
• Here, we report updated efficacy data for IMbrave150 with 12 mo of additional follow-up (median follow-up: 15.6 mo). Page 3. Study design. Key eligibility. Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal A review of the phase 3 IMbrave150 trial comparing atezolizumab-bevacizumab vs standard of care, sorafenib, as initial therapy
Atezolizumab and bevacizumab for upfront unresectable HCC Dr. Li, Assistant Clinical Professor, City of Hope, shares his impressions of the IMBRAVE 150 study particularly relating to patient Full Podcast: Experts provide an overview of current systemic treatment options for 1st line uHCC,
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides Upcoming IO combinations for advanced HCC
With Prof. Jean-François Dufour about this journal paper: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021 IMbrave150 Phase III Design, Results, and Practical Implications
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy
Peter R. Galle, MD, the director of the Medical Department at the University Medical Center Mainz and president-elect of the Dr. Kim, Professor of Medicine, Moffit Cancer Center, describes the IMBRAVE 150 phase 3 study and whether the overall survival Updated efficacy and safety data from IMbrave150: Atezolizumab
Key updates from ASCO GI 2021 Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study
An overview of the phase III IMbrave150 trial, inclusion criteria, primary/secondary end points, and practical implications. Website: Introduction. The IMbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) Dr. Li on the Subgroup Analysis of the IMbrave150 Trial in Older Patients With HCC
Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study IMBrave150 Regimen: Managing Varices Treatment of advanced HCC IMbrave - 150 trail || علاج HCC IMbrave المتقدم
IMbrave150: updated data on atezo plus bev versus sorafenib in HCC To our knowledge, IMbrave150 was the first phase 3 trial since 2007 to show a significant and clinically meaningful survival benefit with
Patient-reported outcomes with atezolizumab plus bevacizumab Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III
Impact of IMbrave150 on theadvanced HCC treatment landscape: How dose it improve patient outcomes? IMbrave150 Trial: Combination Therapy in Advanced HCC
Depth and Duration of Response Are Associated with Survival in Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma
Michel Ducreux, ESMO 2018 – Exploring new treatment options for hepatocellular carcinoma New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of
Patient-Reported Outcomes Improve with Combination Treatment for Patients With HCC IMbrave150 Phase III Trial for MHCC
Dr. Kaubisch on Treatment Options for HCC Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the
Checkpoint inhibition in hepatocellular carcinoma Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase III HIMALAYA trial which investigated
Richard S. Finn, MD, discusses the significance of the results presented on the recent IMbrave150 study in unresectable Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing
Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), Additionally, an exploratory analysis of the patients with Vp4 HCC (15%) enrolled on the IMbrave-150 trial also demonstrated improved efficacy
AACR 2021: Dra. Renata D'Alpino aborda a análise do estudo IMbrave150 IMpower-150: EGFR-Mutated Subset Analysis IMbrave150 showed consistent clinically meaningful treatment benefit and safety with 12 mo of additional follow-up.
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma An expert clinical review of data from the EGFR-mutated subset included in the IMpower-150 trial looking at the addition of Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm
An overview of the IMbrave150 phase III trial data as they relate to the management of hepatocellular carcinoma. We met up with Dr Michel Ducreux at ESMO 2018 who provided a brief review of the current treatment landscape for
7/1/2021. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard
Dr.Molham Khalil. Jawaban Webinar 5 Years of IMbrave150 - Milestones and Future Opportunities in HCC #Dokter #nilai100
IMbrave150 in Unresectable HCC Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma Mehmet Akce, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of
Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable HCC
Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC The role of sorafenib in the first-line treatment of HCC as seen in the IMbrave150 trial. For more resources and information Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer
IMbrave150: Updated overall survival (OS) data from a global ASCO GI 2021: trial updates
Study Details | NCT03434379 | A Study of Atezolizumab in Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of immune
Real-world experience of Impower150 regimen for EGFR+ NSCLC The IMbrave150 trial showed significantly better overall survival and progression-free survival outcomes with atezolizumab plus bevacizumab than Ghassan K. Abou-Alfa, MD, MBA, leads a discussion on the management of varices occurring in patients with metastatic
Dra. Renata D'Alpino, Oncologista Clínica do Grupo Oncoclínicas e Diretora Científica do Grupo Brasileiro de Tumores In this animated video article, we present the phase III HIMALAYA study, which investigated tremelimumab and durvalumab for David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, and consultant medical oncologist in the
Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable James J. Harding, MD, regional director of Early Drug Development at Memorial Sloan Kettering Cancer Center, discusses the
TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) IMbrave150 Trial: Frontline Treatment of Advanced HCC
Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 Prof Richard Finn speaks to ecancer in an online interview for the virtual AACR 2021 meeting about the updated safety and This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease.
Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular Dr. Harding on the Goal of the IMbrave150 trial in HCC Andreas Kaubisch, MD, associate attending physician, Montefiore Medical Center, Albert Einstein College of Medicine, discusses
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma An influx of treatments are emerging against hepatocellular carcinoma (HCC), a common malignancy with huge unmet needs,
IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based HCC podcast series part 1: The use of IO in unresectable HCC
The use of Immunotherapy (IO) in unresectable Hepatocellular Carcinoma (HCC) Impact of IMbrave150 Trial: APAC Expert Review Now Published